bevacizumab,olaparib
Roche,Merck,Astrazeneca
['lynparza', 'merck', 'astrazeneca']
astrazeneca and merck arrived at #esmo22 with long-term data on their blockbuster cancer drug and european confab staple lynparza, which ushered in the parp inhibitor market in december 2014. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs